Medtronic, a global leader in healthcare technology, launched its new transcatheter aortic valve, Evolut™ FX+, in India. The valve is designed to help improve treatment for patients with severe aortic stenosis, especially those who may need future coronary procedures. The Evolut FX+ TAVI system facilitates easier coronary access while maintaining the proven performance of the Evolut™ platform, based on CoreValve™ technology.

医疗器械领域的全球领导者美敦力公司在印度推出了其新型经导管主动脉瓣膜Evolut™ FX+。该瓣膜旨在帮助改善重度主动脉瓣狭窄患者的治疗，尤其是那些未来可能需要进行冠状动脉手术的患者。Evolut FX+ TAVI系统在保持基于CoreValve™技术的Evolut™平台的可靠性能的同时，还能更方便地进行冠状动脉通路。

It was approved by the Central Drugs Standard Control Organization (CDSCO) on June 10, 2025, paving the way for its launch in India. .

它于2025年6月10日获得中央药品标准控制组织（CDSCO）的批准，为其在印度的上市铺平了道路。

The main innovation of Evolut FX+ is its new frame with bigger windows to reduce frame interference while using guide catheters, especially during complex coronary procedures. The system continues to deliver the key advantages that clinicians have come to expect from previous Evolut valves. The system provides market leading valve performance including durable low gradients, which are important for long-term heart function.

Evolut FX+的主要创新在于其新框架设计，更大的窗口可以减少在使用引导导管时的框架干扰，尤其是在复杂的冠状动脉手术中。该系统继续提供临床医生对之前Evolut瓣膜所期望的关键优势。系统提供了市场领先的瓣膜性能，包括持久的低压差，这对长期心脏功能至关重要。

This makes it a strong alternative for patients at risk of coronary disease while supporting long-term treatment needs. .

这使得它成为冠心病风险患者的强有力替代选择，同时支持长期治疗需求。

The introduction of Evolut FX+ in India marks a significant advancement in transcatheter aortic valve therapy and reinforces Medtronic’s leadership in structural heart innovation. With enhanced coronary access and proven hemodynamic performance, the Evolut FX+ empowers physicians to deliver both immediate procedural success and sustained long-term care.  This milestone underscores Medtronic’s steadfast dedication to broadening access to advanced therapies and driving innovation in cardiovascular care and treatment across India..

Evolut FX+在印度的推出标志着经导管主动脉瓣治疗领域的重大进步，进一步巩固了美敦力在结构性心脏病创新方面的领导地位。凭借增强的冠状动脉通路和经过验证的血液动力学性能，Evolut FX+使医生能够在实现即时手术成功的同时提供长期持续的护理。这一里程碑彰显了美敦力致力于扩大先进治疗技术的可及性，并推动印度心血管护理和治疗领域的创新。

Commenting on the product launch by Medtronic,

在评论美敦力的产品发布时，

Prateek Tiwari, Senior Director Neuroscience & Speciality Therapies, Medtronic

普拉蒂克·蒂瓦里，美敦力神经科学与特种疗法高级总监

The launch of Evolut FX+ in India marks a meaningful step forward in transcatheter valve therapy. With its enhanced coronary access and proven hemodynamic performance, FX+ empowers physicians to deliver confident care—not just during the initial procedure, but throughout the patient’s lifetime. By bringing this innovation to India, we are advancing Medtronic’s mission to alleviate pain, restore health, and extend life, while expanding access to future-ready solutions for structural heart disease..

Evolut FX+在印度的推出标志着经导管瓣膜治疗向前迈出了有意义的一步。凭借其增强的冠状动脉通路和经过验证的血液动力学性能，FX+使医生能够在患者初诊乃至整个生命过程中提供信心满满的护理。通过将这一创新技术引入印度，我们正在推动美敦力减轻病痛、恢复健康、延长生命的使命，同时为结构性心脏病扩大未来可用的解决方案。

Evolut FX+ keeps the same tissue structure, valve design, and inflow strength as earlier models, ensuring consistency and reliability. For heart teams, FX+ provides a modern solution that simplifies future coronary treatments, increases patient access to TAVR, and maintains familiar clinical practices.

Evolut FX+ 保持了与早期型号相同的组织结构、瓣膜设计和流入强度，确保了一致性和可靠性。对于心脏团队而言，FX+ 提供了一种现代化的解决方案，简化了未来的冠状动脉治疗，增加了患者接受 TAVR 的机会，并维持了熟悉的临床实践。

With this launch, Medtronic reinforces its commitment to expanding patient access to innovative therapies, helping more patients benefit from advanced treatment options for structural heart disease. .

通过此次发布，美敦力进一步践行了其扩展患者获取创新疗法渠道的承诺，帮助更多患者受益于结构性心脏病的先进治疗方案。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找和发现解决方案，大胆攻克人类面临的最严峻健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、永无止境的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多精彩，因为我们致力于推动以洞察力为导向的护理、以人为本的体验，以及为我们的世界创造更好的成果。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。